Telangiectasia hemorrágica hereditaria: tratamiento farmacológico / Pharmacological treatment of hereditary haemorrhagic telangiectasia
Rev. méd. Chile
;
137(5): 695-700, mayo 2009.
Article
in Spanish
| LILACS
| ID: lil-521874
ABSTRACT
Hereditary hemorrhagic telangiectasia (HHT) of Rendu-Osler-Weber disease is a multi system vascular dysplasia characterized by the presence of multiple telangiectasias, mainly affecting mucosal tissue and arterial-venous connections. It commonly affects lungs, liver and central nervous system. Bleeding is the most common symptom and its treatment can be surgical or pharmacological. We herein review the systemic therapy that attempts to minimize bleeding as well as blood transfusion therapy. Blood therapy and fibrinolytic treatment especially aminocaproic acid and tranexamic acid are discussed. Danazol, hormone therapy and other less common drugs used in the treatment of HHT are also reviewed.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Telangiectasia, Hereditary Hemorrhagic
Limits:
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2009
Type:
Article
Affiliation country:
Spain
Institution/Affiliation country:
Hospital da Barbanza/ES
Similar
MEDLINE
...
LILACS
LIS